Skip to content
Chemoprotection
Radioprotection
Anti-Cancer Research
Discovery Research
Additional Resources

Cancer Discovery, September 2021

Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity

View Publication

Publication highlighted in The Scientist

View Article

Clinical Cancer Research, July 2021

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

View Publication

2019 ESMO Congress

ALRN-6924 and Palbociclib in Patients with MDM2 Amplified or MDM2/CDK4 Co-amplified Tumors: Interim Analysis

View Poster

Nature Communications, May 2018

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

View Publication

Science Translational Medicine, April 2018

Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia

View Publication

Publication highlighted in The Hematologist

View Article

2018 ASH Annual Meeting and Exposition

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

View Poster

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

View Poster

2018 San Antonio Breast Cancer Symposium

The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, and the CDK4/6 inhibitors palbociclib or abemaciclib synergistically enhance each other’s in vitro and in vivo anticancer activity

View Poster

The stapled peptide ALRN‐6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab‐paclitaxel in TP53 wild‐type MCF‐7 breast cancer models

View Poster

2018 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium

Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies

View Poster

2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models

View Poster

2017 ASH Annual Meeting and Exposition

In Vitro and Preclinical In Vivo Evidence Support MDMX/MDM2 as Common Vulnerabilities Across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the Alpha-Helical P53 Stapled Peptide ALRN-6924

View Poster

Dual Inhibition of MDMX and MDM2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia

View Poster

2017 ASCO Annual Meeting

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas

View Abstract
View Presentation

Abstract highlighted in Journal of Clinical Oncology (ASCO Special article)

View Article

Interested in partnering with Aileron?
Please contact us.